Publicaciones en colaboración con investigadores/as de University of Tübingen (19)

2024

  1. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715

  2. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

2023

  1. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

    Bone Marrow Transplantation, Vol. 58, Núm. 11, pp. 1182-1188

  2. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

    Advances in Therapy, Vol. 40, Núm. 5, pp. 2412-2425

  3. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

    Blood cancer journal

2022

  1. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

2020

  1. Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma

    Clinical and Translational Science, Vol. 13, Núm. 6, pp. 1345-1354

2019

  1. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation

    Haematologica, Vol. 104, Núm. 5, pp. 929-936

  2. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

    The Lancet, Vol. 393, Núm. 10168, pp. 253-264

2018

  1. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR

    Haematologica, Vol. 103, Núm. 12, pp. 2079-2087

  2. Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

    Leukemia, Vol. 32, Núm. 7, pp. 1542-1560

2017

  1. Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci

    Nature Genetics, Vol. 49, Núm. 7, pp. 993-1004

  2. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the European myeloma network

    Leukemia, Vol. 2017

2014

  1. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

    Leukemia, Vol. 28, Núm. 8, pp. 1573-1585

2008

  1. CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking

    International Journal of Immunopathology and Pharmacology, Vol. 21, Núm. 4, pp. 797-806

  2. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma

    Leukemia, Vol. 22, Núm. 6, pp. 1250-1255

2007

  1. Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria

    European Journal of Clinical Investigation, Vol. 37, Núm. 6, pp. 435-453

2004

  1. The European Competence Network on Mastocytosis (ECNM)

    Wiener Klinische Wochenschrift, Vol. 116, Núm. 19-20, pp. 647-651

2001

  1. Variable expression of activation-linked surface antigens on human mast cells in health and disease

    Immunological Reviews, Vol. 179, pp. 74-81